Melqart Asset Management’s Cidara Therapeutics CDTX Stock Holding History

Melqart Asset Management’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-26,461	Closed	-$5.84M	–	44
2025 Q4	$5.84M	Buy	+26,461	New	+$4.28M	0.58%	36

Melqart Asset Management's CDTX Position: Q1 2026 in Review

Melqart Asset Management sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 26,461 shares — an estimated $5.84M sold.

Melqart Asset Management first reported a position in CDTX in Q4 2025 and held it in 1 quarter. The position peaked at $5.84M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

Melqart Asset Management reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
Melqart Asset Management sold 26,461 Cidara Therapeutics shares in Q1 2026, an estimated $5.84M.
Melqart Asset Management first reported a position in Cidara Therapeutics in Q4 2025 and held it in 1 quarter.
Melqart Asset Management's Cidara Therapeutics position peaked at $5.84M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on Melqart Asset Management's 13F filing for Q1 2026, filed 12 May 2026.